A recent publication in Science has proposed that cationic amphiphilic drugs repurposed for COVID-19 typically use phosholipidosis as their antiviral mechanism of action in cells but will have no in vivo efficacy. On the contrary, our viewpoint, supported by additional experimental data for similar cationic amphiphilic drugs, indicates that many of these molecules have both in vitro and in vivo efficacy with no reported phospholipidosis, and therefore, this class of compounds should not be avoided but further explored, as we continue the search for broad spectrum antivirals.

中文翻译：

---

捍卫可能导致药物性磷脂病的抗病毒阳离子两亲性药物

《科学》杂志最近发表的一篇文章提出，用于 ​​COVID-19 的阳离子两亲性药物通常使用磷脂沉积症作为其在细胞中的抗病毒作用机制，但在体内没有功效。相反，我们的观点，得到类似阳离子两亲药物的额外实验数据的支持，表明这些分子中的许多分子具有体外和体内功效，没有报道磷脂病，因此，这类化合物不应避免，但应进一步探索，因为我们继续寻找广谱抗病毒药物。